Kyowa Kirin’s Istradefylline (KW-6002) Receives EMA’s MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson’s disease Experiencing “Off” Time

 Kyowa Kirin’s Istradefylline (KW-6002) Receives EMA’s MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson’s disease Experiencing “Off” Time

Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership

Shots:

  • The approval is based on trials assessing KW-6002 vs PBO across EU, the US and Japan in patients with PD taking a stable dose of levodopa-based regimens with/out other PD medications
  • The candidate will serve as an adjunctive treatment to the PD patients which is validated by the EMA and is now under review
  • Istradefylline is a selective adenosine A2A receptor antagonist administered orally and is approved in Japan & the US in Mar 2013, & Aug 2019, to improve “wearing-off” phenomenon in patients with PD on levodopa-containing preparations and as an adjunctive treatment to levodopa/carbidopa in adults with PD experiencing “off” episodes respectively

Click here to read full press release/ article | Ref: Kyowa Kirin | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post